Header

UZH-Logo

Maintenance Infos

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma


Weller, M; Gorlia, T; Cairncross, J G; van den Bent, M J; Mason, W; Belanger, K; Brandes, A A; Bogdahn, U; Macdonald, D R; Forsyth, P; Rossetti, A O; Lacombe, D; Mirimanoff, R-O; Vecht, C J; Stupp, R (2011). Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology, 77(12):1156-1164.

Abstract

VPA may be preferred over an EIAED in patients with glioblastoma who require an AED during TMZ-based chemoradiotherapy. Future studies are needed to determine whether VPA increases TMZ bioavailability or acts as an inhibitor of histone deacetylases and thereby sensitizes for radiochemotherapy in vivo.

Abstract

VPA may be preferred over an EIAED in patients with glioblastoma who require an AED during TMZ-based chemoradiotherapy. Future studies are needed to determine whether VPA increases TMZ bioavailability or acts as an inhibitor of histone deacetylases and thereby sensitizes for radiochemotherapy in vivo.

Statistics

Citations

Dimensions.ai Metrics
125 citations in Web of Science®
153 citations in Scopus®
160 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

2 downloads since deposited on 10 Nov 2011
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2011
Deposited On:10 Nov 2011 14:13
Last Modified:17 Feb 2018 13:47
Publisher:American Academy of Neurology
ISSN:0028-3878
OA Status:Closed
Publisher DOI:https://doi.org/10.1212/WNL.0b013e31822f02e1
PubMed ID:21880994

Download